Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 211

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment

Open access
Valla, Dominique-Charles, Chevallier, Michele, Marcellin, Patrick, Payen, Jean-Louis, Trepo, Christian, Fonck, Marianne, Bourliere, Marc, Boucher, Evelyne, Miguet, Jean-Philippe, Parlier, David, Lemonnier, Catherine, Opolon, Pierre·1999·Hepatology

Abstract

To examine the effects of interferon (IFN) therapy on clinical, biochemical, and histological features in patients with compensated hepatitis C virus (HCV)–related cirrhosis, we have conducted a randomized, controlled trial of IFN therapy versus observation. Eight centers included a total of 99 patients with biopsy–proven cirrhosis. IFN–α2b, 3 million units three times per week, or no antiviral therapy was given for 48 weeks. Twenty–three patients dropped out. End–of–treatment biochemical response was not observed in any of the 39 controls but was observed in 6 of the 47 treated patients (P < .02); sustained biochemical response was obtained in only 2 treated patients. Controls and treated patients did not significantly differ with regard to the changes in serum level of albumin, bilirubin, α–fetoprotein, in plasma prothrombin, in histological activity, or liver collagen content. During trial or follow–up (160 ± 57 weeks), hepatocellular carcinoma developed in 9 controls and 5 treated patients (NS); decompensation of cirrhosis occurred in 5 controls and 7 treated patients. Seven controls and 10 treated patients died. In conclusion, in patients with compensated HCV–related cirrhosis, a 48–week course of IFN therapy is safe and is able to induce end–of–treatment biochemical response in a significant proportion of patients. However, a 48–week course of IFN therapy usually fails to achieve sustained response and, within the limit of this study, did not significantly improve the 3–year outcome. Therefore, a longer course of IFN therapy or combination therapy with ribavirin should be evaluated in patients with HCV–related cirrhosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.510290616

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 211

Metadata

Authors
Valla, D.-C., Chevallier, M., Marcellin, P., Payen, J.-L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.-P., Parlier, D., Lemonnier, C., & Opolon, P.
Venue
Hepatology
Published
1999-06
Volume
29
Issue
6
Pages
1870-1875
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2096121062
Cited by
211
References
2
FWCI
9.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment. https://app.cochat.ai/papers/10.1002/hep.510290616
The paper
Valla, D.-C., Chevallier, M., Marcellin, P., Payen, J.-L., Trepo, C., Fonck, M., Bourliere, M., Boucher, E., Miguet, J.-P., Parlier, D., Lemonnier, C., & Opolon, P. (1999). Treatment of Hepatitis C Virus-Related Cirrhosis: A Randomized, Controlled Trial of Interferon Alfa–2B Versus No Treatment. Hepatology. https://doi.org/10.1002/hep.510290616

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.